Leerink spotlights Novartis’ late-stage stars plus one utility player — suggesting where it could make deals
Over the last year Novartis has been building a rep as something of a penny pincher among the pharma giants. It’s extended its restless search …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
